The findings suggested that inhaled budesonide reduced the risk of urgent care or hospitalization by 90 percent within the study period, the school said. The study also found that the drug had a “quicker resolution of fever, symptoms, and fewer persistent symptoms” after 28 days.

Source: Asthma drug reduces hospitalization for COVID-19: study | TheHill